Newsroom

HOLMDEL, N.J.--(BUSINESS WIRE)--Vonage, azienda del gruppo Ericsson (NASDAQ: ERIC), oggi ha annunciato di essere stata classificata nella categoria Leader nel 2026 IDC MarketScape per il settore Worldwide Communications Engagement Platforms (CEP). Vonage ritiene che questo riconoscimento rifletta la piattaforma completa di comunicazioni di Vonage che consente alle imprese di ridefinire il coinvolgimento dei clienti e dei dipendenti su scala globale. IDC MarketScape: Worldwide Communications Eng...

FOLSOM, Calif.--(BUSINESS WIRE)--PowerSchool, a leading provider of cloud-based software for K-12 education, has been named a Gold Stevie® Award winner in the 24th Annual American Business Awards®. PowerSchool PowerBuddy™ won the Use of Artificial Intelligence in EdTech category for the second consecutive year. PowerSchool earned the honor for PowerBuddy, its secure, AI-powered assistant, designed to support teachers, students, families, and administrators. PowerBuddy simplifies data analysis a...

LONDON--(BUSINESS WIRE)--  Re: Nationwide Building Society (N Covered Bonds) EUR 500,000,000.00 MATURING: 04-May-2027 ISIN: XS2812616147 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 05-May-2026 TO 03-Aug-2026 HAS BEEN FIXED AT 2.38 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 03-Aug-2026 WILL AMOUNT TO: EUR 2,973,750.00 PER EUR 500,000,000.00 DENOMINATION  ...

HOLMDEL, N.J.--(BUSINESS WIRE)--Vonage, filiale d'Ericsson (NASDAQ : ERIC), a annoncé aujourd'hui avoir été classée dans la catégorie « Leaders » du rapport IDC MarketScape de 2026 consacré au secteur des plateformes internationales d'engagement client (CEP). Vonage estime que cette distinction reflète la qualité de sa plateforme de communication complète, qui permet aux entreprises de repenser l'engagement de leurs clients et de leurs employés dans le monde. Le rapport IDC MarketScape : Worldw...

SHANGHAI, Chine et JERSEY CITY, New Jersey--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) et Organon (NYSE : OGN) a annoncé aujourd’hui que la Commission européenne (CE) a accordé une autorisation de mise sur le marché pour POHERDY® (pertuzumab) 420 mg/14 ml en solution injectable pour usage intraveineux, le premier et unique médicament biosimilaire de PERJETA (pertuzumab) approuvé en Europe, pour toutes les indications du produit de référence.1 « En tant que premier, et actuellemen...

LOS ANGELES & LONDON & VEVEY, Switzerland--(BUSINESS WIRE)--CreativeX, the system of control for creative, content, and media, and CreatorIQ, the global operating system for creator-led growth, today announced an industry-first integration — developed in collaboration with Nestlé — to unify creator marketing and paid media workflows under one system. The integration marks a new chapter in how global brands can treat creator content: not as a separate channel to manage, but as a core input into...

DALLAS--(BUSINESS WIRE)--The Board of Directors of Jacobs (NYSE: J) has declared a quarterly cash dividend payable to shareholders in the amount of $0.36 per share of Jacobs common stock. This dividend will be paid on June 19, 2026, to shareholders of record as of the close of business on May 22, 2026. About Jacobs At Jacobs, we're challenging today to reinvent tomorrow – delivering outcomes and solutions for the world's most complex challenges. With approximately $12 billion in annual revenue...

LONDON--(BUSINESS WIRE)--  Xtrackers (IE) plc Investment Company with Variable Capital Registered Office: 78 Sir John Rogerson's Quay, Dublin 2, Ireland Registration number: 393802 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Dublin, 29 April 2026 This announcement is to inform the shareholders of the sub-funds listed in the table below (each a Sub-Fund, and together the Sub-Funds) (the Shareholders) on behalf of the board of directors of the Compa...

SALT LAKE CITY--(BUSINESS WIRE)--Matthew L. Hardy today announced the release of “Deterministic Convergence: Biological Systems, Architecture, and the Search for Hidden Order,” a new book introducing a systems architecture framework for understanding complex biological behavior, genomic interpretation, and individualized medicine. The book argues that modern genomics has produced extraordinary visibility into biological parts, but still lacks a sufficient framework for understanding how those p...

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) en Organon (NYSE: OGN) maakten vandaag bekend dat de Europese Commissie (EC) marketinggoedkeuring heeft verleend voor POHERDY® (pertuzumab) 420 mg/14 mL injectie voor intraveneus gebruik, de eerste en enige goedgekeurde biosimilar voor PERJETA (pertuzumab) in Europa, voor alle indicaties van het referentieproduct.1 “Als eerste en momenteel enige biosimilar voor pertuzumab in Europa, markeert de goedke...